Circadian clock gene Per2 downregulation in non‑small cell lung cancer is associated with tumour progression and metastasis

Xiang,Run; Cui,Yue; Wang,Yanping; Xie,Tianpeng; Yang,Xiaojun; Wang,Zhu; Li,Juan; Li,Qiang

doi:10.3892/or.2018.6704

Circadian clock gene Per2 downregulation in non‑small cell lung cancer is associated with tumour progression and metastasis

Authors:
- Run Xiang
- Yue Cui
- Yanping Wang
- Tianpeng Xie
- Xiaojun Yang
- Zhu Wang
- Juan Li
- Qiang Li
View Affiliations

Affiliations: Department of Thoracic Surgery, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan 610041, P.R. China, Department of Thoracic Surgery, First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan 650000, P.R. China, Laboratory of Molecular Diagnosis of Cancer, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P.R. China, Department of Thoracic Surgery, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan 610041, P.R. China, Laboratory of Molecular Diagnosis of Cancer, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P.R. China, Department of Chemotherapy, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan 610041, P.R. China
Published online on: September 13, 2018 https://doi.org/10.3892/or.2018.6704
Pages: 3040-3048

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Period2 (Per2) is a key circadian clock gene, and its deregulation contributes to tumour development, including breast cancer. However, the biological function and clinicopathological significance of Per2 in non‑small cell lung cancer (NSCLC) remain unclear. The present study aimed to explore the role of Per2 and its relative clinical significance in NSCLC. To analyse Per2 expression in NSCLC specimens, reverse transcription‑quantitative polymerase chain reaction was performed, and the results indicated that Per2 expression was markedly downregulated in 83.87% (26/31) of NSCLC samples compared with their adjacent matched tissues. Increased Per2 expression was associated with increased differentiation (P<0.01) and reduced lymph node metastasis (P<0.0001). Functional studies identified that enhancing Per2 expression in A549 cells by lentivirus transduction not only significantly suppressed cell growth, migration and invasion (P<0.05) but also inhibited NSCLC growth and metastasis in vivo. Animal studies and histopathological analysis identified that Per2 expression in A549 cells not only markedly increased expression of tumour anti‑oncogenes Bax, P53 and P21 but also inhibited expression of pro‑oncogenes vascular endothelial growth factor, CD44 and c‑Myc. These results indicate that the loss of Per2 is one of the factors underlying tumourigenesis in NSCLC, and it may function as a novel molecular target for NSCLC.

View Figures

View References

1	Torre LA, Siegel RL and Jemal A: Lung Cancer Statistics. Adv Exp Med Biol. 893:1–19. 2016. View Article : Google Scholar : PubMed/NCBI
2	Schabath MB, Giuliano AR, Thompson ZJ, Amankwah EK, Gray JE, Fenstermacher DA, Jonathan KA, Beg AA and Haura EB: TNFRSF10B polymorphisms and haplotypes associated with increased risk of death in non-small cell lung cancer. Carcinogenesis. 34:2525–2530. 2013. View Article : Google Scholar : PubMed/NCBI
3	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
4	Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: GLOBOCAN 2008: Cancer Incidence and Mortality Worldwide. IARC Cancerbase No, 10International Agency for Research on Cancer. Lyon: 2010, View Article : Google Scholar : PubMed/NCBI
5	Bechet D: Magnesium in health & disease. Magnesium Res. 29:602016.
6	Cardinali DP: The human body circadian: How the biologic clock influences sleep and emotion. Neuro Endocrinol Lett. 21:9–15. 2000.PubMed/NCBI
7	Liu B, Xu K, Jiang Y and Li X: Aberrant expression of Per1, Per2 and Per3 and their prognostic relevance in non-small cell lung cancer. Int J Clin Exp Pathol. 7:7863–7871. 2014.PubMed/NCBI
8	Chen-Goodspeed M and Lee CC: Tumor suppression and circadian function. J Biol Rhythms. 22:291–298. 2007. View Article : Google Scholar : PubMed/NCBI
9	Gery S, Komatsu N, Kawamata N, Miller CW, Desmond J, Virk RK, Marchevsky A, Mckenna R, Taguchi H and Koeffler HP: Epigenetic silencing of the candidate tumor suppressor gene Per1 in non-small cell lung cancer. Clin Cancer Res. 13:1399–1404. 2007. View Article : Google Scholar : PubMed/NCBI
10	Couto P, Miranda D, Vieira R, Vilhena A, De Marco L and Bastos-Rodrigues L: Association between CLOCK, PER3 and CCRN4L with non-small cell lung cancer in Brazilian patients. Mol Med Rep. 10:435–440. 2014. View Article : Google Scholar : PubMed/NCBI
11	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2^−ΔΔCT method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
12	Retnam L, Chatikavanij P, Kunjara P, Paramastri YA, Goh YM, Hussein FN, Mutalib AR and Poosala S: Laws, Regulations, guidelines and standards for animal care and use for scientific purposes in the countries of Singapore, Thailand, Indonesia, Malaysia, and India. ILAR J. 57:312–323. 2016. View Article : Google Scholar : PubMed/NCBI
13	Chung S, Son GH and Kim K: Circadian rhythm of adrenal glucocorticoid: Its regulation and clinical implications. Biochim Biophys Acta. 1812:581–591. 2011. View Article : Google Scholar : PubMed/NCBI
14	Savvidis C and Koutsilieris M: Circadian rhythm disruption in cancer biology. Mol Med. 18:1249–1660. 2012. View Article : Google Scholar : PubMed/NCBI
15	Winter SL, Bosnoyan-Collins L, Pinnaduwage D and Andrulis IL: Expression of the circadian clock genes Per1 and Per2 in sporadic and familial breast tumors. Neoplasia. 9:797–800. 2007. View Article : Google Scholar : PubMed/NCBI
16	Kuo SJ, Chen ST, Yeh KT, Hou MF, Chang YS, Hsu NC and Chang JG: Disturbance of circadian gene expression in breast cancer. Virchows Archiv. 454:467–474. 2009. View Article : Google Scholar : PubMed/NCBI
17	Chu LW, Zhu Y, Yu K, Zheng T, Yu H, Zhang Y, Sesterhenn I, Chokkalingam AP, Danforth KN, Shen MC, et al: Variants in circadian genes and prostate cancer risk: A population-based study in China. Prostate Cancer Prostatic Dis. 11:342–348. 2008. View Article : Google Scholar : PubMed/NCBI
18	Hwang-Verslues WW, Chang PH, Jeng YM, Kuo WH, Chiang PH, Chang YC, Hsieh TH, Su FY, Lin LC, Abbondante S, et al: Loss of corepressor PER2 under hypoxia up-regulates OCT1-mediated EMT gene expression and enhances tumor malignancy. Proc Natl Acad Sci USA. 110:12331–12336. 2013. View Article : Google Scholar : PubMed/NCBI
19	Miller BH, McDearmon EL, Panda S, Hayes KR, Zhang J, Andrews JL, Antoch MP, Walker JR, Esser KA, Hogenesch JB and Takahashi JS: Circadian and CLOCK-controlled regulation of the mouse transcriptome and cell proliferation. Proc Natl Acad Sci USA. 104:3342–3347. 2007. View Article : Google Scholar : PubMed/NCBI
20	Chi C, He ZF, Liu Y, Lin XM and Sun CC: Expression and clinical significance of circadian gene Per2 in non-small cell lung cancer. Zhonghua Zhong Liu Za Zhi. 35:129–131. 2013.(In Chinese). PubMed/NCBI
21	McQueen CM, Schmitt EE, Sarkar TR, Elswood J, Metz RP, Earnest D, Rijnkels M and Porter WW: PER2 regulation of mammary gland development. Development. 145:pii: dev157966. 2018. View Article : Google Scholar : PubMed/NCBI
22	Fu L and Lee CC: The circadian clock: Pacemaker and tumour suppressor. Nat Rev Cancer. 3:350–361. 2003. View Article : Google Scholar : PubMed/NCBI
23	Takahashi JS, Hong HK, Ko CH and McDearmon EL: The genetics of mammalian circadian order and disorder: Implications for physiology and disease. Nat Rev Genet. 9:764–775. 2008. View Article : Google Scholar : PubMed/NCBI
24	Levi F, Okyar A, Dulong S, Innominato PF and Clairambault J: Circadian timing in cancer treatments. Annu Rev Pharmacol Toxicol. 50:377–421. 2010. View Article : Google Scholar : PubMed/NCBI
25	Kelleher FC, Rao A and Maguire A: Circadian molecular clocks and cancer. Cancer Lett. 342:9–18. 2014. View Article : Google Scholar : PubMed/NCBI
26	Fu L and Kettner NM: The circadian clock in cancer development and therapy. Prog Mol Biol Transl Sci. 119:221–282. 2013. View Article : Google Scholar : PubMed/NCBI
27	Fu L, Pelicano H, Liu J, Huang P and Lee C: The circadian gene Period2 plays an important role in tumor suppression and DNA damage response in vivo. Cell. 111:41–50. 2002. View Article : Google Scholar : PubMed/NCBI
28	Younger ST, Kenzelmann-Broz D, Jung H, Attardi LD and Rinn JL: Integrative genomic analysis reveals widespread enhancer regulation by p53 in response to DNA damage. Nucleic Acids Res. 43:4447–4462. 2015. View Article : Google Scholar : PubMed/NCBI
29	Garner E and Raj K: Protective mechanisms of p53-p21-pRb proteins against DNA damage-induced cell death. Cell Cycle. 7:277–282. 2008. View Article : Google Scholar : PubMed/NCBI
30	Mirzayans R, Andrais B, Scott A and Murray D: New insights into p53 signaling and cancer cell response to DNA damage: Implications for cancer therapy. J Biomed Biotechnol. 2012:1703252012. View Article : Google Scholar : PubMed/NCBI
31	Okabe T, Kumagai M, Nakajima Y, Shirotake S, Kodaira K, Oyama M, Ueno M and Ikeda M: The impact of HIF1α on the Per2 circadian rhythm in renal cancer cell lines. PLoS One. 9:e1096932014. View Article : Google Scholar : PubMed/NCBI
32	Miyazaki K, Wakabayashi M, Hara Y and Ishida N: Tumor growth suppression in vivo by overexpression of the circadian component, PER2. Genes Cells. 15:351–358. 2010. View Article : Google Scholar : PubMed/NCBI
33	Clark SJ and Melki J: DNA methylation and gene silencing in cancer: Which is the guilty party? Oncogene. 21:5380–5387. 2002. View Article : Google Scholar : PubMed/NCBI
34	Gotoh T, Vila-Caballer M, Santos CS, Liu J, Yang J and Finkielstein CV: The circadian factor Period 2 modulates p53 stability and transcriptional activity in unstressed cells. Mol Biol Cell. 25:3081–3093. 2014. View Article : Google Scholar : PubMed/NCBI
35	Chen ST, Choo KB, Hou MF, Yeh KT, Kuo SJ and Chang JG: Deregulated expression of the PER1, PER2 and PER3 genes in breast cancers. Carcinogenesis. 26:1241–1246. 2005. View Article : Google Scholar : PubMed/NCBI
36	Nagel R, Clijsters L and Agami R: The miRNA-192/194 cluster regulates the Period gene family and the circadian clock. FEBS J. 276:5447–5455. 2009. View Article : Google Scholar : PubMed/NCBI